AzTrials
AzTrials

Multiple MyelomaPhase 1DREAMM 9NCT04091126

Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

A Phase 1 study testing Belantamab mafodotin, Bortezomib and Lenalidomide in people with Multiple Myeloma, run by GlaxoSmithKline at 30 sites in 10 countries.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

This study will evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of belantamab mafodotin in combination with Velcade (bortezomib), Revlimid (lenalidomide), dexamethasone (VRd) and will determine recommended phase 3 dose (RP3D) in adult participants with newly diagnosed multiple myeloma… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Multiple Myeloma
What is being tested?
Belantamab mafodotin, Bortezomib and Lenalidomide
Could I receive a placebo?
No, everyone receives an active treatment
How many people
118 participants
Where
30 sitesin 10 countries
Study dates
18 Dec 2019to 10 Mar 2028
Phase
Phase 1
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Participant must be over 18 years of age inclusive, at the time of signing the informed consent.
  • Diagnosis of multiple myeloma with a requirement for treatment as documented per international myeloma working group (IMWG) criteria.
  • Must have at least one aspect of measurable disease, defined as one of the following:
  • Urine M-protein excretion >=200 mg/24 hours (>=0.2 gram [g]/24 hours), or
  • Serum M-protein concentration >=0.5 grams per deciliter (g/dL) (>=5.0 gram per liter [g/L]), or
  • Serum free light chain (FLC) assay: involved FLC level >=10 milligrams per deciliter (mg/dL) (>=100 milligram per liter [mg/L]) and an abnormal serum free light chain ratio (<0.26 or >1.65).
Show all 17Show fewer
  • Not a candidate for high-dose chemotherapy with autologous stem cell transplant (ASCT) due to presence of significant comorbid condition(s), such as cardiac, pulmonary or other major organ dysfunction that are likely to have a negative impact on tolerability of high dose chemotherapy with stem cell transplantation, as judged by the investigator.
  • Eastern cooperative oncology group (ECOG) status of 0-2
  • Adequate organ system functions as defined by the laboratory assessments listed as following: Absolute neutrophil count (ANC) >=1.5 x 10^9/L; Hemoglobin >=8.0 g/dL; Platelets >=75 x 10^9/L; Total bilirubin <=1.5 x upper limit of normal (ULN); (Isolated bilirubin >1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin is <35%); Alanine aminotransferase (ALT) <=2.5 x ULN; eGFR >=30 mL/minute/1.73 meter^2; Urine Dipstick for protein OR Albumin/creatinine ratio (from spot urine)- Negative/trace (if >=1 plus only eligible if confirmed <=500 mg/gram (56 mg/millimoles [mmol]) by albumin/creatinine ratio (spot urine from first void); Left Ventricular Ejection Fraction (LVEF) by echocardiogram (ECHO) of >=35% participants with low LVEF (per institutional standards), consider referring to cardiology per local standards of care.
  • Sex and Contraception/Barrier Requirements (Female):
  • Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies:
  • Is NOT a woman of childbearing potential (WOCBP) or Due to lenalidomide being a thalidomide analogue with risk for embryofetal toxicity and prescribed under a pregnancy prevention/controlled distribution program, and bortezomib having the potential to cause fetal harm, WOCBP participants will be eligible if they commit to either: abstain continuously from heterosexual sexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR to use birth control as follows: Two methods of reliable birth control (one method that is highly effective and one additional effective (barrier) method), beginning 4 weeks prior to initiating treatment with lenalidomide, during therapy, during dose interruptions and continuing for 4 weeks following discontinuation of lenalidomide treatment. Thereafter, WOCBP participants must use one method of reliable birth control that is highly effective for a further 3 months following discontinuation of belantamab mafodotin, or a further 6 months following discontinuation of bortezomib, whichever is longer. WOCBP must also agree not to donate eggs (ova, oocytes) for the purpose of reproduction during treatment, during dose interruptions and for 28-days following the last dose of lenalidomide, 4 months following discontinuation of belantamab mafodotin treatment or 7-months following the last dose of bortezomib, whichever is longer. Two negative pregnancy tests must be obtained prior to initiating therapy. The first test should be performed within 10-14 days and the second test within 24 hours prior to prescribing the start of lenalidomide therapy.
  • The participant should not receive lenalidomide until the investigator has verified that the results of these pregnancy tests are negative. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention. The Investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
  • Sex and Contraception/Barrier Requirements (Male):
  • Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
  • Male participants are eligible to participate if they agree to the following from the time of first dose of study treatment until 28-days after the last dose of lenalidomide, 4-months after the last dose of bortezomib, or 6 months after the last dose of belantamab mafodotin, whichever is longer, to allow for clearance of any altered sperm: Refrain from donating sperm - Plus either: - Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR Must agree to use contraception/barrier as detailed below: Agree to use a male condom, even if they have undergone a successful vasectomy, and female partner to use an additional highly effective contraceptive method with a failure rate of <1% per year when having sexual intercourse with a WOCBP. Male participants should also use a condom when having sexual intercourse with pregnant females.
  • Capable of giving signed informed consent.

Who cannot join

  • Smoldering multiple myeloma (SMM).
  • Prior systemic therapy for multiple myeloma, or SMM. NOTE: An emergency course of steroids (defined as no greater than 40 mg of dexamethasone, or equivalent per day for a maximum of 4 days (that is, a total of 160 mg) is permitted. NOTE: Focal palliative radiation is permitted prior to enrollment, provided that it occurred at least 2 weeks prior to the first dose of study drug, that the participant has recovered from radiation-related toxicities, and that the participant did not require corticosteroids for radiation-induced adverse events.
  • Participant is eligible for high dose chemotherapy with ASCT, as determined by a frailty score of 0 as assessed by the IMWG frailty index.
  • Peripheral neuropathy or neuropathic pain Grade 2 or higher, as defined by the national cancer institute (NCI)-common terminology criteria for adverse events (CTCAE) Version 5.
  • Major surgery within 4 weeks prior to the first dose of study drug.
  • Presence of active renal condition (infection, requirement for dialysis or any other significant condition that could affect participant's safety). Participants with isolated proteinuria resulting from multiple myeloma (MM) are eligible, provided they fulfil criteria.
Show all 23Show fewer
  • Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities) that could interfere with participant's safety, obtaining informed consent or compliance to the study procedures.
  • Evidence of active mucosal or internal bleeding uncontrolled by local therapy and not explained by reversible coagulopathy.
  • Current active liver or biliary disease (except for Gilbert's syndrome or asymptomatic gallstones, or otherwise stable chronic liver disease as per the Investigator's assessment).
  • Participants with previous or concurrent malignancies other than multiple myeloma are excluded. Exceptions are surgically treated cervical carcinoma in situ, or any other malignancy that has been considered medically stable for at least 2 years. The participant must not be receiving active therapy, other than hormonal therapy for this disease. Note: Participants with curatively treated non-melanoma skin cancer are allowed without a 2-year restriction.
  • Evidence of cardiovascular risk including any of following: Evidence of current clinically significant untreated arrhythmias, including clinically significant electrocardiogram (ECG) abnormalities including second degree (Mobitz Type II) or third degree atrioventricular (AV) block; History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within 3 months of Screening.; Class III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system; Uncontrolled hypertension.
  • Active infection requiring treatment.
  • Known human immunodeficiency virus (HIV) infection.
  • Presence of hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb), at Screening or within 3 months prior to first dose of study treatment.
  • Positive hepatitis C antibody test result.
  • Current corneal epithelial disease except for mild punctate keratopathy. Note: Participants with mild punctate keratopathy are allowed.
  • Intolerance or contraindications to anti-viral prophylaxis.
  • Unable to tolerate antithrombotic prophylaxis.
  • AL amyloidosis (light chain amyloidosis), active polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma proliferative disorder, skin changes (POEMS) syndrome or active plasma cell leukemia at the time of screening.
  • Exhibiting clinical signs of or has a known history of meningeal or central nervous system involvement by multiple myeloma.
  • Known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to drugs chemically related to belantamab mafodotin, or any of the components of the study treatment.
  • Use of an investigational drug within 14 days or five half-lives (whichever is longer) preceding the first dose of study drug.
  • Plasmapheresis within 7 days prior to the first dose of study drug.

Trial locations and contacts

30 sites in 10 countries.

30 sites in 10 countries

Spain7 sites

  • GSK Investigational Site

    Badalona, Barcelona, 08916

  • GSK Investigational Site

    Barcelona, 08036

  • GSK Investigational Site

    Madrid, 28027

  • GSK Investigational Site

    Málaga, 29010

  • GSK Investigational Site

    PamplonaNavarra, 31008

  • GSK Investigational Site

    Pozuelo de AlarcOn Madr, 28223

  • GSK Investigational Site

    Santander, 39008

Other trials in Spain

Germany4 sites

  • GSK Investigational Site

    Dresden, 01307

  • GSK Investigational Site

    Hamburg, 20246

  • GSK Investigational Site

    Schwerin, 19049

  • GSK Investigational Site

    Tübingen, 72076

Other trials in Germany

United States3 sites

  • GSK Investigational Site

    Charlotte, North Carolina, 28204

  • GSK Investigational Site

    Madison, Wisconsin, 53792-0001

  • GSK Investigational Site

    Westwood, Kansas, 66205

Other trials in United States

Australia3 sites

  • GSK Investigational Site

    Clayton, Victoria, 3168

  • GSK Investigational Site

    Fitzroy, Victoria, 3065

  • GSK Investigational Site

    Newcastle, New South Wales, 2298

Other trials in Australia

South Korea3 sites

  • GSK Investigational Site

    Seoul, 03080

  • GSK Investigational Site

    Seoul, 03722

  • GSK Investigational Site

    Seoul, 137-701

Other trials in South Korea

United Kingdom3 sites

  • GSK Investigational Site

    Leicester, LE1 5WW

  • GSK Investigational Site

    Oxford, OX3 7LE

  • GSK Investigational Site

    Southampton, Hampshire, SO16 6YD

Other trials in United Kingdom

Canada2 sites

  • GSK Investigational Site

    Edmonton, Alberta, T6G 1Z2

  • GSK Investigational Site

    London, Ontario, N6A 5W9

Other trials in Canada

Italy2 sites

  • GSK Investigational Site

    Bologna, 40138

  • GSK Investigational Site

    Meldola FC, 47014

Other trials in Italy

Poland2 sites

  • GSK Investigational Site

    Lublin, 20-081

  • GSK Investigational Site

    Poznan, 61-848

Other trials in Poland

France1 site

  • GSK Investigational Site

    Poitiers, 86021

Other trials in France

About this study

Official title: A Phase 1, Randomized, Dose and Schedule Evaluation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Belantamab Mafodotin Administered in Combination With Standard of Care in Participants With Newly Diagnosed Multiple Myeloma

This study will evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of belantamab mafodotin in combination with Velcade (bortezomib), Revlimid (lenalidomide), dexamethasone (VRd) and will determine recommended phase 3 dose (RP3D) in adult participants with newly diagnosed multiple myeloma (NDMM). Participants will receive the combination of bortezomib, lenalidomide and dexamethasone (VRd) on a 3-week cycle until cycle 8, followed by the combination of lenalidomide and dexamethasone (Rd) on a 4-week cycle thereafter as per dosing schedule. Participants will receive belantamab mafodotin on a schedule that is dependent on the cohort to which they are assigned. Belantamab mafodotin will be administered in combination with VRd every 3 weeks (Q3W), every 6 weeks (Q6W), or every 9 weeks (Q9W) to Cycle 8, and then in combination with Rd every 4 weeks (Q4W), every 8 weeks (Q8W), or every 12 weeks (Q12W) thereafter. Participants will complete an End of Treatment (EOT) visit at the point of study treatment discontinuation, followed by a Safety Follow-up visit 70 days after EOT.

Being tested
Belantamab mafodotin, Bortezomib, Lenalidomide, Dexamethasone
Keywords
Bortezomib, Lenalidomide, dexamethasone, VRd, Belantamab mafodotin, Newly diagnosed multiple myeloma, RP3D, DREAMM 9
Medical subject headings
Multiple Myeloma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Belantamab mafodotinDrug

    Selected doses of belantamab mafodotin will be administered as intravenous infusion.

  • BortezomibDrug

    Bortezomib will be administered subcutaneously or intravenously approximately 1 hour after the belantamab mafodotin infusion until Cycle 8.

  • LenalidomideDrug

    Lenalidomide will be administered as 25 or 10 mg orally, depending upon renal function.

  • DexamethasoneDrug

    Dexamethasone will be administered orally as 20 mg in cycles 1-8 and 40 mg in Cycle 9 onwards.

Study groups in NCT04091126
Study groupRoleWhat they receive
Cohort 1: belantamab mafodotin 1.9 mg/kg Q3/4W + VRd/RdExperimentalParticipants will receive 1.9 milligram /kilogram (mg/kg) Q3W dose of belantamab mafodotin on Day 1 of every cycle for the first 8 cycles in combination with VRd and Q4W dose in combination with Rd from cycle 9 onwards.
Receives: Drug: Belantamab mafodotin; Drug: Bortezomib; Drug: Lenalidomide; Drug: Dexamethasone
Cohort 2: belantamab mafodotin 1.4 mg/kg Q6/8W + VRd/RdExperimentalParticipants will receive 1.4 mg/kg Q6W dose of belantamab mafodotin on Day 1 of every other cycle for the first 8 cycles in combination with VRd and Q8W dose in combination with Rd from cycle 9 onwards.
Receives: Drug: Belantamab mafodotin; Drug: Bortezomib; Drug: Lenalidomide; Drug: Dexamethasone
Cohort 3: belantamab mafodotin 1.9 mg/kg Q6/8W + VRd/RdExperimentalParticipants will receive 1.9 mg/kg Q6W dose of belantamab mafodotin on Day 1 of every other cycle for the first 8 cycles in combination with VRd and Q8W dose in combination with Rd from cycle 9 onwards.
Receives: Drug: Belantamab mafodotin; Drug: Bortezomib; Drug: Lenalidomide; Drug: Dexamethasone
Cohort 4: belantamab mafodotin 1.0 mg/kg Q3/4W + VRd/RdExperimentalParticipants will receive 1.0 mg/kg Q3W dose of belantamab mafodotin on Day 1 of every cycle for the first 8 cycles in combination with VRd and Q4W dose in combination with Rd from cycle 9 onwards.
Receives: Drug: Belantamab mafodotin; Drug: Bortezomib; Drug: Lenalidomide; Drug: Dexamethasone
Cohort 5: belantamab mafodotin 1.4 mg/kg Q3/4W + VRd/RdExperimentalParticipants will receive 1.4 mg/kg Q3W dose of belantamab mafodotin on Day 1 of every cycle for the first 8 cycles in combination with VRd and Q4W dose in combination with Rd from cycle 9 onwards.
Receives: Drug: Belantamab mafodotin; Drug: Bortezomib; Drug: Lenalidomide; Drug: Dexamethasone
Cohort 6: belantamab mafodotin 1.4mg/kg cycle 1, 1.0 mg/kg Q9/12W Cycle 4+VRd/RdExperimentalBased on emerging data from Cohort 2-5, participants will receive 1.4 mg/kg dose of belantamab mafodotin on Day 1 of cycle 1, followed by 1.0 mg/kg dose on Day 1 of every third cycle from cycle 4 onwards, in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.
Receives: Drug: Belantamab mafodotin; Drug: Bortezomib; Drug: Lenalidomide; Drug: Dexamethasone
Cohort 7: belantamab mafodotin 1.9 mg/kg Cycle 1, 1.4 mg/kg Q9/12W Cycle 4+VRd/RdExperimentalBased on emerging data from Cohort 2-5, participants will receive 1.9 mg/kg dose of belantamab mafodotin of cycle 1, followed by 1.4 mg/kg on Day 1 of every third cycle from cycle 4 in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.
Receives: Drug: Belantamab mafodotin; Drug: Bortezomib; Drug: Lenalidomide; Drug: Dexamethasone
Cohort 8a : belantamab mafodotin 1.9 mg/kg Cycle 1,4; 1.4 mg/kg Q9/12W from Cycle 7 +VRd/RdExperimentalBased on emerging data from Cohort 6-7, participants will receive 1.9 mg/kg dose of belantamab mafodotin on Day 1 of cycle 1 and cycle 4, followed by 1.4 mg/kg on Day 1 of every third cycle from cycle 7 onwards, in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.
Receives: Drug: Belantamab mafodotin; Drug: Bortezomib; Drug: Lenalidomide; Drug: Dexamethasone
Cohort 8b: belantamab mafodotin 1.4 mg/kg Cycle 1,3; 1.0 mg/kg Q9/12W from Cycle 6 +VRd/RdExperimentalBased on emerging data from Cohort 6-7, participants will receive 1.4 mg/kg IV dose of belantamab mafodotin on Day 1 of cycle 1 and cycle 3, then 1.0 mg/kg on Day 1 of every third cycle from cycle 6 in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.
Receives: Drug: Belantamab mafodotin; Drug: Bortezomib; Drug: Lenalidomide; Drug: Dexamethasone
Cohort 8c: belantamab mafodotin 1.0 mg/kg Cycle 1,5;1.0 mg/kg Q9/12W from Cycle 9 +VRd/RdExperimentalBased on emerging data from Cohort 6-7, participants will receive 1.0 mg/kg IV dose of belantamab mafodotin on Day 1 of cycle 1 and cycle 5, then 1.0 mg/kg on day 1 of every third cycle from cycle 9 in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.
Receives: Drug: Belantamab mafodotin; Drug: Bortezomib; Drug: Lenalidomide; Drug: Dexamethasone

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With Dose-limiting Toxicities (DLTs) of Belantamab Mafodotin

    Criteria for DLT included hematologic indicators including Grade(G) 3-5 febrile neutropenia, G4 neutropenia >7 days, G3 or greater thrombocytopenia accompanied by clinically significant bleeding; non-hematologic criteria, including Any G3/4 non-hematologic toxicity, G5 non hematologic toxicity, G3 or greater corneal toxicity; Liver toxicity meeting prespecified GSK liver stopping criteria. Severity was graded using National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.

    Measured: Up to 63 days

  2. Number of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were to be coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

    Measured: Up to approximately 284 weeks

Secondary outcomes (22)

  1. Lenalidomide Relative Dose Intensity (RDI) After Treatment With Belantamab Mafodotin in Combination With VRd

    Relative Dose Intensity (RDI) is defined as the percentage of the amount of a drug actually delivered (actual dose intensity [DI]) relative to the amount planned (planned DI).

    Measured: Up to 168 days

  2. Bortezomib RDI After Treatment With Belantamab Mafodotin in Combination With VRd

    Relative Dose Intensity (RDI) is defined as the percentage of the amount of a drug actually delivered (actual dose intensity [DI]) relative to the amount planned (planned DI).

    Measured: Up to 168 days

  3. Cumulative Administered Dose of Belantamab Mafodotin After Treatment in Combination With VRd

    Cumulative Dose is sum of the actual dose administered during each infusion for a participant.

    Measured: Up to 84 days

  4. Area Under the Concentration Time Curve From 0 to 504 Hours [AUC (0 - 504 Hours)] of Belantamab Mafodotin

    Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin. The last PK assessment used to derive AUC0-504h was intended to be collected approximately 504 hours (21 days) after the start of the first infusion. Depending on the dosing schedule, this assessment occurred either at the Day 22 visit (±3 days) for participants in the Q6/8W and Q9/12W cohorts or at the Cycle 2 Day 1 pre-dose visit for participants in the Q3W cohorts. Therefore, samples collected at Day 22 or Cycle 2 Day 1 predose represent the protocol-defined PK assessment performed at approximately 504 hours after Dose 1.

    Measured: Day 1 Cycle 1 Pre-Dose, End of Infusion (EOI); Anytime between Day 8 and Day 15 after Start of Infusion (SOI); Cycle 2 Day 1 Pre-Dose (up to Day 22 or at the end of the Cycle 1 dosing period)

  5. Maximum Plasma Concentration (Cmax) of Belantamab Mafodotin

    Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin.

    Measured: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)

  6. Time to Reach Cmax (Tmax) of Belantamab Mafodotin

    Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin.

    Measured: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)

  7. Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) of Belantamab Mafodotin

    Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin. C-trough were measured prior to the next dose for each cycle.

    Measured: Pre-dose at Day 1 of Cycle 1, 2, 3, 4, 5, 7, 10, 13, 14, 15, 16, 17, 23, 24, 27, 28, 29, 30, 31, 34, 36, 37, 41, 43, 49

  8. Observed Plasma Concentration at the End of Infusion (C-EOI) of Belantamab Mafodotin

    Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin.

    Measured: End of infusion at Day 1 on C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C24, C25, C26, C27 (up to approximately 81 weeks)

  9. Time of Last Observed Quantifiable Concentration (Tlast) of Belantamab Mafodotin

    Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin. The last PK assessment used to derive Tlast was intended to be collected approximately 504 hours (21 days) after the start of the first infusion. Depending on the dosing schedule, this assessment occurred either at the Day 22 visit (±3 days) for participants in the Q6/8W and Q9/12W cohorts or at the Cycle 2 Day 1 pre-dose visit for participants in the Q3W cohorts. Therefore, samples collected at Day 22 or Cycle 2 Day 1 predose represent the protocol-defined PK assessment performed at approximately 504 hours after Dose 1.

    Measured: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI); Cycle 2 Day 1 Pre-Dose (up to Day 22 or at the end of the Cycle 1 dosing period)

  10. Clearance of Belantamab Mafodotin

    Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin.

    Measured: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)

  11. Volume of Distribution at Steady State (Vss) of Belantamab Mafodotin

    Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin.

    Measured: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)

  12. Apparent Terminal Half Life (t1/2) of Belantamab Mafodotin

    Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin.

    Measured: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)

  13. AUC (0 - 504 Hour) of Cys-mcMMAF

    Blood Samples were collected for Pharmacokinetic analysis of cys-mcMMAF. The last PK assessment used to derive AUC0-504h was intended to be collected approximately 504 hours (21 days) after the start of the first infusion. Depending on the dosing schedule, this assessment occurred either at the Day 22 visit (±3 days) for participants in the Q6/8W and Q9/12W cohorts or at the Cycle 2 Day 1 pre-dose visit for participants in the Q3W cohorts. Therefore, samples collected at Day 22 or Cycle 2 Day 1 predose represent the protocol-defined PK assessment performed at approximately 504 hours after Dose 1.

    Measured: Day 1 Cycle 1 Pre-Dose, End of Infusion (EOI); Anytime between Day 8 and Day 15 after Start of Infusion (SOI); Cycle 2 Day 1 Pre-Dose (up to Day 22 or at the end of the Cycle 1 dosing period)

  14. Cmax of Cys-mcMMAF

    Blood Samples were collected for Pharmacokinetic analysis of cys-mcMMAF.

    Measured: D1 C1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72h; D8-15 post Start of Infusion(SOI); 22d post-SOI; PD & EOI at D1 of C2-7,10,14-17,19,22,26; PD at D1 of C13,18,21,23,24,27-31,34,36,37,39,41,43,46,49; End of Treatment(EOT) (~C52, up to ~234weeks)

  15. Time to Reach Cmax (Tmax) of Cys-mcMMAF

    Blood Samples were collected for Pharmacokinetic analysis of cys-mcMMAF.

    Measured: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)

  16. Observed Plasma C-EOI of Cys-mcMMAF

    Blood Samples were collected for Pharmacokinetic analysis of cys-mcMMAF.

    Measured: End of infusion at Day 1 on C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C24, C25, C26, C27 (up to approximately 81 weeks)

  17. Tlast of Cys-mcMMAF

    Blood Samples were collected for Pharmacokinetic analysis of cys-mcMMAF.

    Measured: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI)

  18. Number of Participants With Positive Post-baseline Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin

    Serum samples were collected for the analysis of ADAs of anti-belantamab mafodotin.

    Measured: Up to approximately 234 weeks

  19. Titers of ADAs Against Belantamab Mafodotin

    Serum Samples were collected for the analysis of ADAs of anti-belantamab mafodotin.

    Measured: Up to approximately 234 weeks

  20. Overall Response Rate (ORR)

    ORR was defined as the percentage of participants with a confirmed partial response (PR) or better (i.e., PR, very good partial response [VGPR], complete response [CR] and stringent complete response [sCR]), according to the International Myeloma Working Group (IMWG) Response Criteria. CR: negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND <5% plasmacytomas in the bone marrow; sCR: CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR: serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component <100 mg/24 hour (h); PR: ≥50% reduction of serum M-protein and reduction in 24-h urinary M-protein by ≥90% or to <200 mg/24 h.

    Measured: Up to approximately 284 weeks

  21. Complete Response Rate (CRR)

    CRR is defined as the percentage of participants with a confirmed complete response (CR) or better (i.e. CR and stringent complete response [sCR]), according to the IMWG Response Criteria. CR: negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND <5% plasmacytomas in the bone marrow; sCR: CR as above PLUS normal serum FLC assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.

    Measured: Up to approximately 284 weeks

  22. Percentage of Participants With Confirmed VGPR or Better

    VGPR or better (i.e. VGPR, CR, sCR) is defined as - VGPR: serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component <100 mg/24 h , CR: negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND <5% plasmacytomas in the bone marrow; sCR: CR as above PLUS normal serum FLC assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.

    Measured: Up to approximately 284 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Sep 2019
  2. Study start18 Dec 2019
  3. Primary completion2 Jun 2025
  4. Study completion10 Mar 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Sequential
Model description
The study will evaluate different doses/dose schedules of belantamab mafodotin in combination with Velcade (bortezomib), Revlimid (lenalidomide), dexamethasone, (VRd) in up to 8 cohorts and will determine the Recommended Phase 3 dose (RP3D).
Masking
None (open label)
Enrolment
118 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04091126
Sponsor's protocol ID
209664
Other IDs
2023-507060-39, 2019-003047-30, 2023-507060-39-00, 2023, 2019
Acronym
DREAMM 9
Status last verified
Nov 2026
First submitted
13 Sep 2019
Last updated
9 Nov 2026
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: IPD for this study will be made available via the Clinical Study Data Request site.
Expanded access
Available

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Belantamab mafodotin, Bortezomib and Lenalidomide in people with Multiple Myeloma, run by GlaxoSmithKline at 30 sites in 10 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 17 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 9 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 30 sites in Spain, Germany, United States, Australia, South Korea and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 9 Nov 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With Dose-limiting Toxicities (DLTs) of Belantamab Mafodotin (time frame: Up to 63 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04091126.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in